1. Yamayoshi S, Yasuhara A, Ito M, Akasaka O, Nakamura M, Nakachi I, Koga M, Mitamura K, Yagi K, Maeda K, Kato H, Nojima M, Pattinson D, Ogura T, Baba R, Fujita K, Nagai H, Yamamoto S, Saito M, Adachi E, Ochi J, Hattori SI, Suzuki T, Miyazato Y, Chiba S, Okuda M, Murakami J, Hamabata T, Iwatsuki-Horimoto K, Nakajima H, Mitsuya H, Omagari N, Sugaya N, Yotsuyanagi H, Kawaoka Y. Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. EClinicalMedicine. 2021. 32. 100734. Doi: 10.1016/j.eclinm.2021.100734
2. 氏江美智子、山吉誠也、河岡義裕 2021 新型コロナウイルス感染症に対する治療薬とワクチン 周産期医学 51(3): 363-367.
3. Imai M, Halfmann PJ, Yamayoshi S, Iwatsuki-Horimoto K, Chiba S, Watanabe T, Nakajima N, Ito M, Kuroda M, Kiso M, Maemura T, Takahashi K, Loeber S, Hatta M, Koga M, Nagai H, Yamamoto S, Saito M, Adachi E, Akasaka O, Nakamura M, Nakachi I, Ogura T, Baba R, Fujita K, Ochi J, Mitamura K, Kato H, Nakajima H, Yagi K, Hattori SI, Maeda K, Suzuki T, Miyazato Y, Valdez R, Gherasim C, Furusawa Y, Okuda M, Ujie M, Lopes TJS, Yasuhara A, Ueki H, Sakai-Tagawa Y, Eisfeld AJ, Baczenas JJ, Baker DA, O'Connor SL, O'Connor DH, Fukushi S, Fujimoto T,….., Kawaoka Y. 2021. Characterization of a new SARS-CoV-2 variant that emerged in Brazil. Proc Natl Acad Sci U S A 118:e2106535118. doi: 10.1073/pnas.2106535118
4. 山吉誠也 抗体療法が海外では利用されていますが、新型コロナウイルスの変異株にも有効でしょうか? インフルエンザ[その他の呼吸器感染症]2021, 22(3): 42.
5. Changrob S, Fu Y, Guthmiller JJ, Halfmann PJ, Li L, Stamper CT, Dugan HL, Accola M, Rehrauer W, Zheng NY, Huang M, Wang J, Erickson SA, Utset HA, Graves HM, Amanat F, Sather DN, Krammer F, Kawaoka Y, Wilson PC. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike. mBio. 2021, 12, 6, e0297521. doi: 10.1128/mBio.02975-21.
6. Dugan HL, Stamper CT, Li L, Changrob S, Asby NW, Halfmann PJ, Zheng N-Y, Huang M, Shaw DG, Cobb MS, Erickson SA, Guthmiller JJ, Stovicek O, Wang J, Winkler ES, Madariaga ML, Shanmugarajah K, Jansen MO, Amanat F, Stewart I, Utset HA, Huang J, Nelson CA, Dai Y-N, Hall PD, Jedrzejczak RP, Joachimiak A, Krammer F, Diamond MS, Fremont DH, Kawaoka Y, Wilson PC, Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. Immunity 2021, 54, (6), 1290-1303. doi: 10.1016/j.immuni.2021.05.001
7. 浦木隆太、山吉誠也、河岡義裕 COVID-19の変異ウイルスについて インフルエンザ[その他の呼吸器感染症]2022, 23(1): 37-44.
8. Pattinson D, Jester P, Guan L, Yamayoshi S, Chiba S, Presler R, Rao H, Iwatsuki-Horimoto K, Ikeda N, Hagihara M, Uchida T, Mitamura K, Halfmann P, Neumann G, Kawaoka Y. A Novel Method to Reduce ELISA Serial Dilution Assay Workload Applied to SARS-CoV-2 and Seasonal HCoVs. Viruses 2022, 14, 562. doi: 10.3390/v14030562
9. Fujii T, Hagihara M, Mitamura K, Nakashima S, Ohara S, Uchida T, Inoue M, Okuda M, Yasuhara A, Murakami J, Duong C, Iwatsuki-Horimoto K, Yamayoshi S, Kawaoka Y. 2022. Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan. Intern Med 9209-21. doi: 10.2169/internalmedicine.9209-21
10. 山吉誠也 国内でも抗体療法が承認されていますが、新型コロナウイルスの変異ウイルスにも有効でしょうか。インフルエンザ[その他の呼吸器感染症]2022, 23(1): 60.